(19)
(11) EP 4 267 611 A1

(12)

(43) Date of publication:
01.11.2023 Bulletin 2023/44

(21) Application number: 21908157.7

(22) Date of filing: 23.12.2021
(51) International Patent Classification (IPC): 
C07K 16/10(2006.01)
A61K 39/42(2006.01)
A61P 31/14(2006.01)
(52) Cooperative Patent Classification (CPC):
C07K 16/10; A61P 31/14; C07K 2317/76; C07K 2317/92; C07K 2317/34
(86) International application number:
PCT/AU2021/051550
(87) International publication number:
WO 2022/133545 (30.06.2022 Gazette 2022/26)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(30) Priority: 23.12.2020 AU 2020904813

(71) Applicant: Garvan Institute of Medical Research
Darlinghurst, NSW 2010 (AU)

(72) Inventors:
  • MAZIGI, Ohan
    Petersham, NSW 2049 (AU)
  • LANGLEY, David
    Marsfield, NSW 2122 (AU)
  • SCHOFIELD, Peter
    Carlton, NSW 2218 (AU)
  • CHRIST, Daniel
    Annandale, NSW 2038 (AU)

(74) Representative: Lee, Nicholas John et al
Kilburn & Strode LLP Lacon London 84 Theobalds Road
London WC1X 8NL
London WC1X 8NL (GB)

   


(54) SARS-COV-2 ANTIBODIES